Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
1.
Cancer Gene Ther ; 20(3): 201-7, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23392202

ABSTRACT

Pluripotent hematopoietic stem cells (HSC) are critical in sustaining and constantly renewing the blood and immune system. The ability to alter biological characteristics of HSC by introducing and expressing genes would have enormous therapeutic possibilities. Previous unpublished work suggested that human HSC co-express CD34 (cluster of differentiation 34; an HSC marker) and CD155 (poliovirus receptor; also called Necl-5/Tage4/PVR/CD155). In the present study, we demonstrate the co-expression of CD34 and CD155 in primary human HSC. In addition, we demonstrate that poliovirus infects and replicates in human hematopoietic progenitor cell lines. Finally, we show that poliovirus replicates in CD34+ enriched primary HSC. CD34+ enriched HSC co-express CD155 and support poliovirus replication. These data may help further understanding of poliovirus spread in vivo and also demonstrate that human HSC may be amenable for gene therapy via poliovirus-capsid-based vectors. They may also help elucidate the normal function of Necl-5/Tage4/PVR/CD155.


Subject(s)
Antigens, CD34/metabolism , Hematopoietic Stem Cells/metabolism , Hematopoietic Stem Cells/virology , Poliovirus/physiology , Virus Replication , Bone Marrow Cells/metabolism , Bone Marrow Cells/virology , Cell Line , Cells, Cultured , Humans
2.
Cancer Gene Ther ; 18(12): 906-12, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21904395

ABSTRACT

Mesothelioma is an incurable cancer of the pleura with a life expectancy of less than 1 year. On the basis of in vivo efficacy seen with the herpes simplex virus type 1 thymidine kinase (HSVtk) suicide gene-modified PA1STK cell line and ganciclovir (GCV) in a murine model of mesothelioma, a first in humans, clinical trial was designed for this therapeutic concept. The study was a phase I clinical trial using direct infusion of escalating doses of HSVtk suicide gene-modified PA1STK cells directly into tumor-associated pleural effusions followed by 7 days of intravenous GCV infusion. Therapeutic levels of GCV in both serum and pleura were achieved within 1 h, and GCV trough levels remained above the therapeutic threshold for the duration of GCV treatment. The treatment was well tolerated without any Grade 3 or 4 toxicity observed. Significant inductions of both Th1 and Th2 cytokines up to 20-fold over baseline were observed. No significant differences were seen between serum and pleura cytokine profiles, with the exception of interleukin-10, which was consistently elevated in the pleura specimens. No objective radiographic responses were observed. The data indicate significant immunological responses and validate the principal anti-tumor mechanisms observed in preclinical models of mesothelioma in a human clinical trial.


Subject(s)
Ganciclovir/therapeutic use , Genes, Transgenic, Suicide/genetics , Genetic Therapy , Mesothelioma/therapy , Pleural Diseases/therapy , Thymidine Kinase/genetics , Thymidine Kinase/metabolism , Adult , Aged , Aged, 80 and over , Cell Line, Tumor , Female , Ganciclovir/administration & dosage , Ganciclovir/adverse effects , Herpesvirus 1, Human/genetics , Humans , Infusions, Intravenous , Interleukin-10/analysis , Interleukin-10/metabolism , Male , Mesothelioma/drug therapy , Mesothelioma/pathology , Middle Aged , Neoplasm Staging , Pleural Diseases/drug therapy , Pleural Diseases/pathology , Th1-Th2 Balance
3.
Bone Marrow Transplant ; 43(1): 61-7, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18724395

ABSTRACT

In an effort to reduce the incidence and severity of acute GVHD (aGVHD), we have developed a new prophylaxis regimen combining cyclosporine and MTX with a short 30-day course of low-dose (500 mg per day) mycophenolate mofetil. This regimen was studied prospectively 100 patients undergoing HLA-matched and 1-antigen-mismatched allogeneic peripheral blood SCT from related donors. The cumulative incidence of aGVHD was 16% (grades II-IV (9.5%) and grades III-IV (1%)). The cumulative incidence of chronic GVHD (cGVHD) was 53% with 28% extensive cGVHD. The cumulative incidence of transplant-related mortality at 100 days and 3 years were 6 and 13%. The estimated probabilities of disease-free survival at 3 years in standard- and high-risk patients were 77 and 30%, respectively (P<0.0001). The estimated probabilities of overall survival at 3 years in standard- and high-risk patients were 77 and 37%, respectively (P<0.0001). These data show a substantial decrease in the risk of developing aGVHD without an increase in relapse or any adverse impact on survival in standard-risk patients.


Subject(s)
Cyclosporine/therapeutic use , Graft vs Host Disease/prevention & control , Hematopoietic Stem Cell Transplantation/methods , Immunosuppressive Agents/therapeutic use , Methotrexate/therapeutic use , Mycophenolic Acid/analogs & derivatives , Adolescent , Adult , Cohort Studies , Cyclosporine/adverse effects , Disease-Free Survival , Female , Graft vs Host Disease/immunology , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Immunosuppressive Agents/adverse effects , Male , Methotrexate/adverse effects , Middle Aged , Mucositis , Mycophenolic Acid/adverse effects , Mycophenolic Acid/therapeutic use , Prospective Studies , Transplantation Conditioning , Young Adult
4.
Cancer Gene Ther ; 13(5): 460-8, 2006 May.
Article in English | MEDLINE | ID: mdl-16282988

ABSTRACT

In principle, transient nongenetic modification of a noninfectious gene transfer virus enabling a one time infection and transduction of human cells could eliminate the risk of formation of replication competent virus. Formation of a molecular conjugate vector by conjugation of noninfective ecotropic murine Moloney leukemia virus to polylysine (eMMLV-PL) enabled high-efficiency transduction of human HPC using in vitro and in vivo assays. Xenotransplanted NOD-SCID mice durably expressed the transgene in human leukocytes and human progenitor cells with eMMLV-PL achieving three-fold increased transduction efficiency when directly compared to optimized amphotropic MMLV (aMMLV) transduction. Both aMMLV and eMMLV assembled conjugate vectors showed similar transduction efficiency indicating predominant polylysine-mediated uptake. Integration of retroviral sequences was determined from individual human HPC recovered from eMMLV-PL-xenotransplanted animals. This simple and versatile concept of conjugate gene transfer vectors has the potential to enhance transduction efficiency as well as to improve certain safety aspects of human gene therapy. Moreover, because it permits effective cellular internalization of particles, this concept of molecular conjugates can be used as research tool to investigate the interactions of otherwise noninfectious viruses or modified viral particles at the genomic level.


Subject(s)
Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/metabolism , Moloney murine leukemia virus/chemistry , Moloney murine leukemia virus/genetics , Polylysine/chemistry , Transduction, Genetic/methods , Animals , Genetic Vectors/genetics , Humans , Mice , Mice, Inbred NOD , Mice, SCID , Transplantation, Heterologous
5.
Ann Oncol ; 16(1): 97-101, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15598945

ABSTRACT

BACKGROUND: The purpose of this study was to compare quality of life and overall toxicity in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine-gemcitabine (VG) or carboplatin-paclitaxel (Taxol) (CP). PATIENTS AND METHODS: A total of 165 previously untreated patients were randomized to the two regimens. Quality of life was assessed by the Lung Cancer Symptom Scale (LCSS). Overall toxicity and secondary efficacy end points were evaluated by standard WHO criteria. RESULTS: There was no significant difference in overall quality of life between the two treatments. Neutropenia, thrombocytopenia, peripheral neuropathy, and alopecia, were more common in the CP arm, whereas constipation was more frequent in the VG arm. Response rates were 14.6% in the VG arm and 16.9% in the CP arm. Median survival times were 7.8 and 8.6 months, and 1 year survival rates were 38.4% and 31.9%, respectively. CONCLUSIONS: Patients treated with VG experienced lower toxicity, but overall quality of life was similar in both arms. Efficacy seemed comparable between VG and CP. Our study shows that VG is a viable alternative to platinum-based chemotherapy in patients with advanced NSCLC.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Deoxycytidine/analogs & derivatives , Lung Neoplasms/drug therapy , Vinblastine/analogs & derivatives , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carboplatin/administration & dosage , Carcinoma, Non-Small-Cell Lung/pathology , Deoxycytidine/administration & dosage , Female , Humans , Infusions, Intravenous , Lung Neoplasms/pathology , Male , Middle Aged , Paclitaxel/administration & dosage , Quality of Life , Survival Analysis , Treatment Outcome , Vinblastine/administration & dosage , Vinorelbine , Gemcitabine
7.
Biotechniques ; 32(2): 279-80, 282-4, 286, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11848403

ABSTRACT

Marine experimental stem cell transplantations require the accurate discrimination and quantification of donor cells from host cells. A Y-chromosome-specific, quantitative real-time PCR (kinetic PCR) protocol for blood-derived DNA was developed. The assay sensitivity was extremely high with accurate detection of only 10 pg (six copies of Y target DNA) in a variable background of female DNA background ranging from 2.5 to 50 ng. The dynamic range of the assay provided accurate results ranging from 2.2 x 10(-2)% to 100% of male DNA in female background. The kinetic PCR assay can be used in all mouse strains, and a sample size as low as 2.5 ng total DNA is sufficient for analysis. Therefore, kinetic PCR allows engraftment kinetic studies on repeated blood draws of individual animals with no need for sacrifice. Compared to conventional PCR, the assay is much simplified, as neither the accurate adjustment of sample DNA concentration nor a post-reaction analysis procedure is required. The procedure is simple, free of radioactivity, and permits a throughput of 500-600 reactions per day.


Subject(s)
DNA/blood , Polymerase Chain Reaction/methods , Animals , Chimera , Female , Hematopoietic Stem Cell Transplantation , Kinetics , Male , Mice , Mice, Inbred C57BL , Reproducibility of Results , Sensitivity and Specificity , Sex Characteristics , Y Chromosome
8.
Cell Mol Life Sci ; 59(12): 2083-7, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12568334

ABSTRACT

Retrovirus-derived vectors are currently the preferred vectors used for human gene therapy protocols. Serious safety concerns persist, however, which are specifically related to the formation of a replication-competent virus, and no synthesis method currently employed precludes its formation with certainty. For many cell types, a low transduction efficiency results in insufficient therapeutic benefit. We describe the development of a molecular conjugate system, which permits transient chemical modification of a retrovirus with polylysine. This modification not only introduces additional safety features over standard unmodified retrovirus vectors, but also provides enhanced transduction efficiency.


Subject(s)
Genetic Therapy/methods , Genetic Vectors , Polylysine/chemistry , Retroviridae/chemistry , Retroviridae/genetics , Transduction, Genetic , Animals , Humans , Polylysine/metabolism , Retroviridae/metabolism
9.
Blood ; 98(12): 3309-14, 2001 Dec 01.
Article in English | MEDLINE | ID: mdl-11719368

ABSTRACT

Many mutant mice deficient in leukocyte adhesion molecules display altered hematopoiesis and neutrophilia. This study investigated whether peripheral blood neutrophil concentrations in these mice are elevated as a result of accumulation of neutrophils in the circulation or altered hematopoiesis mediated by a disrupted regulatory feedback loop. Chimeric mice were generated by transplanting various ratios of CD18(+/+) and CD18(-/-) unfractionated bone marrow cells into lethally irradiated wild-type mice, resulting in approximately 0%, 10%, 50%, 90%, or 100% CD18 null neutrophils in the blood. The presence of only 10% CD18(+/+) neutrophils was sufficient to prevent the severe neutrophilia seen in mice reconstituted with CD18(-/-) bone marrow cells. These data show that the neutrophilia in CD18(-/-) mice is not caused by enhanced neutrophil survival or the inability of neutrophils to leave the vascular compartment. In CD18(-/-), CD18(-/-)E(-/-), CD18(-/-)P(-/-), EP(-/-), and EPI(-/-) mice, levels of granulocyte colony-stimulating factor (G-CSF) and interleukin-17 (IL-17) were elevated in proportion to the neutrophilia seen in these mice, regardless of the underlying mutation. Antibiotic treatment or the propensity to develop skin lesions did not correlate with neutrophil counts. Blocking IL-17 or G-CSF function in vivo significantly reduced neutrophil counts in severely neutrophilic mice by approximately 50% (P <.05) or 70% (P <.01), respectively. These data show that peripheral blood neutrophil numbers are regulated by a feedback loop involving G-CSF and IL-17 and that this feedback loop is disrupted when neutrophils cannot migrate into peripheral tissues.


Subject(s)
Cell Adhesion Molecules/deficiency , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocytes/physiology , Hematopoiesis , Interleukin-17/pharmacology , Animals , Bone Marrow Transplantation , CD18 Antigens/analysis , CD18 Antigens/physiology , E-Selectin/analysis , E-Selectin/physiology , Feedback , Granulocyte Colony-Stimulating Factor/antagonists & inhibitors , Granulocyte Colony-Stimulating Factor/blood , Granulocyte Colony-Stimulating Factor/physiology , Intercellular Adhesion Molecule-1/analysis , Intercellular Adhesion Molecule-1/physiology , Interleukin-17/antagonists & inhibitors , Interleukin-17/blood , Interleukin-17/physiology , Leukocyte Count , Mice , Mice, Inbred C57BL , Neutrophils/chemistry , Neutrophils/cytology , P-Selectin/analysis , P-Selectin/physiology , Transplantation Chimera
10.
J Clin Invest ; 108(10): 1469-74, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11714738

ABSTRACT

Host defenses are profoundly compromised in HIV-infected hosts due to progressive depletion of CD4+ T lymphocytes. Moreover, deficient CD4+ T lymphocytes impair vaccination approaches to prevent opportunistic infection. Therefore, we investigated a CD4+ T cell-independent vaccine approach to a prototypic AIDS-defining infection, Pneumocystis carinii (PC) pneumonia. Here, we demonstrate that bone marrow-derived dendritic cells (DCs) expressing the murine CD40 ligand, when pulsed ex vivo by PC antigen, elicited significant titers of anti-PC IgG in CD4-deficient mice. Vaccinated animals demonstrated significant protection from PC infection, and this protection was the result of an effective humoral response, since adoptive transfer of CD4-depleted splenocytes or serum conferred this protection to CD4-deficient mice. Western blot analysis of PC antigen revealed that DC-vaccinated, CD4-deficient mice predominantly reacted to a 55-kDa PC antigen. These studies show promise for advances in CD4-independent vaccination against HIV-related pathogens.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Fungal Vaccines/administration & dosage , Pneumocystis/immunology , Pneumonia, Pneumocystis/prevention & control , Adoptive Transfer , Animals , Base Sequence , DNA Primers , Lymphocyte Activation , Male , Mice , Mice, Inbred BALB C
11.
J Virol ; 75(21): 10393-400, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11581407

ABSTRACT

We have previously reported effective gene transfer with a targeted molecular conjugate adenovirus vector through the c-kit receptor in hematopoietic progenitor cell lines. However, a c-kit-targeted recombinant retroviral vector failed to transduce cells, indicating the existence of significant differences for c-kit target gene transfer between these two viruses. Here we demonstrate that conjugation of an adenovirus to a c-kit-retargeted retrovirus vector enables retroviral transduction. This finding suggests the requirement of endosomalysis for successful c-kit-targeted gene transfer. Furthermore, we show efficient gene transfer to, and high transgene expression (66%) in, CD34-selected, c-kit(+) human peripheral blood stem cells using a c-kit-targeted adenovirus vector. These findings may have important implications for future vector development in c-kit-targeted stem cell gene transfer.


Subject(s)
Antigens, CD34/analysis , Gene Transfer, Horizontal , Genetic Therapy , Hematopoietic Stem Cells/metabolism , Proto-Oncogene Proteins c-kit/metabolism , Adenoviridae/genetics , Coxsackie and Adenovirus Receptor-Like Membrane Protein , Genetic Vectors , Humans , Receptors, Virus/analysis , Retroviridae/genetics
12.
Am J Respir Cell Mol Biol ; 25(3): 335-40, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11588011

ABSTRACT

Bacterial pneumonia remains an important cause of morbidity and mortality worldwide, especially in immune-compromised patients. Cytokines and chemokines are critical molecules expressed in response to invading pathogens and are necessary for normal lung bacterial host defenses. Here we show that interleukin (IL)-17, a novel cytokine produced largely by CD4+ T cells, is produced in a compartmentalized fashion in the lung after challenge with Klebsiella pneumoniae. Moreover, overexpression of IL-17 in the pulmonary compartment using a recombinant adenovirus encoding murine IL-17 (AdIL-17) resulted in the local induction of tumor necrosis factor-alpha, IL-1beta, macrophage inflammatory protein-2, and granulocyte colony-stimulating factor (G-CSF); augmented polymorphonuclear leukocyte recruitment; and enhanced bacterial clearance and survival after challenge with K. pneumoniae. However, simultaneous treatment with AdIL-17 provided no survival benefit after intranasal K. pneumoniae challenge. These data show that IL-17 may have a role in priming for enhanced chemokine and G-CSF production in the context of lung infection and that optimally timed gene therapy with IL-17 may augment host defense against bacterial pneumonia.


Subject(s)
Interleukin-17/metabolism , Klebsiella Infections/immunology , Klebsiella pneumoniae/metabolism , Lung/immunology , Pneumonia, Bacterial/immunology , Animals , Bronchoalveolar Lavage Fluid/cytology , Chemokine CXCL2 , Chemokines/metabolism , Granulocyte Colony-Stimulating Factor/metabolism , Humans , Interleukin-1/metabolism , Interleukin-17/genetics , Lung/chemistry , Male , Mice , Mice, Inbred C57BL , Tumor Necrosis Factor-alpha/metabolism
13.
J Exp Med ; 194(4): 519-27, 2001 Aug 20.
Article in English | MEDLINE | ID: mdl-11514607

ABSTRACT

Bacterial pneumonia is an increasing complication of HIV infection and inversely correlates with the CD4(+) lymphocyte count. Interleukin (IL)-17 is a cytokine produced principally by CD4(+) T cells, which induces granulopoiesis via granulocyte colony-stimulating factor (G-CSF) production and induces CXC chemokines. We hypothesized that IL-17 receptor (IL-17R) signaling is critical for G-CSF and CXC chemokine production and lung host defenses. To test this, we used a model of Klebsiella pneumoniae lung infection in mice genetically deficient in IL-17R or in mice overexpressing a soluble IL-17R. IL-17R-deficient mice were exquisitely sensitive to intranasal K. pneumoniae with 100% mortality after 48 h compared with only 40% mortality in controls. IL-17R knockout (KO) mice displayed a significant delay in neutrophil recruitment into the alveolar space, and had greater dissemination of K. pneumoniae compared with control mice. This defect was associated with a significant reduction in steady-state levels of G-CSF and macrophage inflammatory protein (MIP)-2 mRNA and protein in the lung in response to the K. pneumoniae challenge in IL-17R KO mice. Thus, IL-17R signaling is critical for optimal production of G-CSF and MIP-2 and local control of pulmonary K. pneumoniae infection. These data support impaired IL-17R signaling as a potential mechanism by which deficiency of CD4 lymphocytes predisposes to bacterial pneumonia.


Subject(s)
Chemokines, CXC/metabolism , Granulocyte Colony-Stimulating Factor/metabolism , Lung/metabolism , Neutrophils/cytology , Receptors, Interleukin/metabolism , Recombinant Proteins/metabolism , Signal Transduction , Animals , Bronchoalveolar Lavage Fluid , Klebsiella Infections/immunology , Klebsiella pneumoniae/isolation & purification , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Receptors, Interleukin/genetics , Receptors, Interleukin-17 , Recombinant Proteins/genetics
14.
J Immunol ; 167(4): 2081-6, 2001 Aug 15.
Article in English | MEDLINE | ID: mdl-11489991

ABSTRACT

Autologous and allogeneic bone marrow transplantations have evolved as important cancer therapy modalities. For both indications, peripheral blood has been shown to have distinct advantages over bone marrow as the stem cell source. Cytokine combinations for mobilization have enhanced stem cell yield and accelerated engraftment. However, novel mobilizing agents and strategies are needed to further improve clinical outcomes. Within the donor graft, the dynamic equilibrium between T cells and stem cells critically influences engraftment and transplantation results. IL-17 is a cytokine produced almost exclusively from activated T cells. IL-17 was expressed in vivo with adenovirus technology. Here, proof-of-principle studies demonstrate that IL-17 effectively mobilizes hemopoietic precursor cells (CFU-granulocyte-erythrocyte-macrophage-monocyte, CFU-high proliferative potential) and primitive hemopoietic stem cells (Lin(-/low)c-kit(+)Sca1(+)). Moreover, mouse IL-17 adenovirus-mobilized peripheral blood stem cells rescued lethally irradiated mice. Bone marrow was found to be 45-75% of donor origin at 1 year. In secondary recipients, donor-derived bone marrow cells ranged from 45 to 95%. These data show that IL-17 mobilizes stem cells in mice with short- and long-term reconstituting capacity. Additional comparative studies are needed as well as studies in tumor models to refine distinct potential clinical applications for IL-17-mobilized peripheral blood stem cells.


Subject(s)
Hematopoietic Stem Cell Mobilization/methods , Hematopoietic Stem Cell Transplantation , Interleukin-17/physiology , Animals , Cell Division/genetics , Cell Division/immunology , Cell Survival/genetics , Cell Survival/immunology , Female , Genetic Vectors/administration & dosage , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cells/cytology , Immunophenotyping , Interleukin-17/administration & dosage , Interleukin-17/genetics , Leukocyte Count , Male , Mice , Mice, Inbred C57BL , Radiation Chimera/immunology , Stem Cells/cytology
15.
J Immunol ; 167(2): 1004-13, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11441109

ABSTRACT

T cell IL-17 displays proinflammatory properties and is expressed in the synovium of patients with rheumatoid arthritis. Its contribution to the arthritic process has not been identified. Here, we show that blocking of endogenous IL-17 in the autoimmune collagen-induced arthritis model results in suppression of arthritis. Also, joint damage was significantly reduced. In contrast, overexpression of IL-17 enhanced collagen arthritis. Moreover, adenoviral IL-17 injected in the knee joint of type II collagen-immunized mice accelerated the onset and aggravated the synovial inflammation at the site. Radiographic and histologic analysis showed markedly increased joint destruction. Elevated levels of IL-1beta protein were found in synovial tissue. Intriguingly, blocking of IL-1alphabeta with neutralizing Abs had no effect on the IL-17-induced inflammation and joint damage in the knee joint, implying an IL-1 independent pathway. This direct potency of IL-17 was underscored in the unabated IL-17-induced exaggeration of bacterial cell wall-induced arthritis in IL-1beta(-/-) mice. In conclusion, this data shows that IL-17 contributes to joint destruction and identifies an IL-1-independent role of IL-17. These findings suggest IL-17 to be a novel target for the treatment of destructive arthritis and may have implications for tissue destruction in other autoimmune diseases.


Subject(s)
Arthritis, Experimental/immunology , Arthritis, Experimental/pathology , Interleukin-17/physiology , Interleukin-1/physiology , Synovial Membrane/immunology , Synovial Membrane/pathology , Adenoviridae/genetics , Adenoviridae/immunology , Animals , Arthritis, Experimental/genetics , Arthritis, Experimental/prevention & control , Arthritis, Infectious/genetics , Arthritis, Infectious/immunology , Arthritis, Infectious/pathology , Disease Models, Animal , Disease Progression , Gene Transfer Techniques , Genetic Vectors/administration & dosage , Genetic Vectors/immunology , Hindlimb , Injections, Intra-Articular , Injections, Intravenous , Interleukin-1/deficiency , Interleukin-1/genetics , Interleukin-1/metabolism , Interleukin-17/antagonists & inhibitors , Interleukin-17/biosynthesis , Interleukin-17/genetics , Male , Mice , Mice, Inbred DBA , Mice, Knockout , Neutrophil Infiltration/genetics , Neutrophil Infiltration/immunology , Neutrophils/pathology , Polysaccharides, Bacterial/toxicity , RNA, Messenger/biosynthesis , Synovial Membrane/metabolism
16.
J Biol Chem ; 276(27): 24601-7, 2001 Jul 06.
Article in English | MEDLINE | ID: mdl-11313337

ABSTRACT

Two significant barriers limit the use of amphotropic retrovirus for human gene transfer protocols: 1) low transduction efficiency in cells with low receptor expression and 2) safety concerns originating from the risk of formation and propagation of replication competent virus in vivo. In principle, if ecotropic retrovirus, which is incapable of infecting human cells, could be transiently modified to effectively transduce human cells, this safety risk could be alleviated. Here we demonstrate that formation of amphotropic retrovirus polylysine molecular conjugates (aMMLV-PL) enhanced gene transfer up to 10-fold in a variety of human cell lines over the equivalent of unconjugated vector (aMMLV). The polylysine modification and formation of ecotropic retrovirus molecular conjugates (eMMLV-PL) permitted effective and stable transduction of different human cell lines as well as primary human bone marrow stroma cells at frequencies of greater than 80%. It is conceivable that this novel ecotropic-based conjugate retrovirus vector could also potentially provide enhanced safety characteristics not only over amphotropic retrovirus vectors but also over genetically tropism-modified recombinant ecotropic vectors. In contrast to genetic modifications, physical or chemical modifications are not propagated. Thus, formation of replication competent eMMLV from conjugates would be self-limited and would not result in virus propagation in humans.


Subject(s)
Gene Transfer Techniques , Retroviridae/genetics , 3T3 Cells , Animals , Avidin , Bone Marrow Cells , Cell Line , Hexadimethrine Bromide , Humans , Lac Operon , Macromolecular Substances , Mice , Polylysine , Restriction Mapping , Stromal Cells , Transduction, Genetic , Transgenes
17.
Alcohol Clin Exp Res ; 25(3): 444-9, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11290857

ABSTRACT

BACKGROUND: Ethanol (EtOH) is known to alter host immune responses and cytokine production. Acute EtOH exposure can suppress tumor necrosis factor (TNF)-alpha production, which attenuates pulmonary defense against infection. Previous studies in our laboratory show that acute EtOH inhibited TNF-alpha production by a posttranscriptional process, namely suppression of TNF-alpha-converting, enzyme-mediated, ectodomain shedding. However, chronic EtOH has been shown to augment TNF-alpha production, and this has been associated with EtOH-induced liver injury. To further characterize this paradoxical effect of EtOH on TNF-alpha production, we developed an in vitro model by using Mono Mac 6 cells, a human monocytic cell line. METHODS: Mono Mac 6 cells were treated with EtOH (0-75 mM) for 1 to 7 days. TNF-alpha production was induced by lipopolysaccharide and phorbol myristate acetate and quantitated by enzyme-linked immunosorbent assay. Generation of reactive oxygen species (ROS) was assayed by using a specific fluorogenic reagent. RESULTS: Acute EtOH initially inhibited lipopolysaccharide/phorbol myristate acetate-induced TNF-alpha production in Mono Mac 6 cells. However, during chronic EtOH exposure, this inhibition was reversed gradually over time. By day 6 after EtOH treatment, Mono Mac 6 cells demonstrated significant up-regulation of TNF-alpha production. Moreover, chronic EtOH induced the generation of ROS in these Mono Mac 6 cells. Scavenging ROS by Mn(III)tetrakis(1-methyl-4pyridyl)porphyrin pentachloride and N-acetyl-L-cysteine attenuated chronic EtOH-enhanced TNF-alpha production. CONCLUSION: These results suggest that ROS induction is involved in EtOH-enhanced TNF-alpha production by monocytes. This study also provides insight into the mechanisms of alteration of TNF-alpha production in different EtOH exposure settings.


Subject(s)
Central Nervous System Depressants/pharmacology , Ethanol/pharmacology , Monocytes/drug effects , Tumor Necrosis Factor-alpha/drug effects , Carcinogens , Cell Line , Dose-Response Relationship, Drug , Humans , Lipopolysaccharides , Monocytes/metabolism , Reactive Oxygen Species/metabolism , Tetradecanoylphorbol Acetate , Tumor Necrosis Factor-alpha/metabolism
18.
Am J Med Sci ; 321(2): 129-36, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11217815

ABSTRACT

BACKGROUND: Targeted, specific receptor mediated gene transfer is a major goal of gene therapy research to accomplish gene transfer exclusively to the desired cell population. METHODS: First, the use of natural receptor for stem cell factor and transferrin receptor-targeted gene transfer using poly-L-lysine-based molecular conjugate vectors was evaluated in a panel of hematopoietic progenitor cell lines. Second, the ability of poly-L-lysine to enhance adenovirus mediated gene transfer efficiency was examined in different cell lines by using recombinant adenovirus-poly-L-lysine molecular conjugate conglomerates (recMCVEGFP). RESULTS: Despite effective ligand internalization receptor, gene expression amplification in receptor positive cell lines was not uniformly observed. Therefore, using a poly-L-lysine-based, receptor-targeted vector, neither transferrin nor natural receptor for stem cell factor mediated gene transfer can be considered a universally applicable procedure that exclusively depends on the presence of receptors on the cell surface; rather, it is a cell specific phenomenon. In our model, poly-L-lysine is the major contributor for gene transfer to hematopoietic progenitor cells, mediating the initial vector-cell binding. Human progenitor cell lines are poorly transduceable with recombinant adenovirus vectors. This new poly-L-lysine-modified, adenovirus-based vector could overcome virus tropism restrictions and consistently achieve very high transduction efficiency (>90%) in cells otherwise refractory to adenovirus gene transfer. CONCLUSIONS: Polylysine-based adenovirus vectors may have promise for situations in which high-efficiency gene transfer with transient high level transgene expression in hematopoietic cells is needed, such as leukemia vaccine protocols or for purging strategies in leukemia cell contaminated stem cell preparations.


Subject(s)
Adenoviruses, Human/genetics , Genetic Vectors/administration & dosage , Hematopoietic Stem Cells/drug effects , Neoplastic Stem Cells/drug effects , Polylysine/pharmacology , Transfection/methods , Carcinoma, Non-Small-Cell Lung/pathology , Cell Adhesion , Cell Line , Coxsackie and Adenovirus Receptor-Like Membrane Protein , Endocytosis , Eye Neoplasms/pathology , Genes, Reporter , Genetic Vectors/genetics , Humans , K562 Cells/drug effects , Leukemia, Megakaryoblastic, Acute/pathology , Leukemia, Monocytic, Acute/pathology , Lung Neoplasms/pathology , Polylysine/administration & dosage , Proto-Oncogene Proteins c-kit/drug effects , Receptors, Transferrin/drug effects , Receptors, Virus/drug effects , Retinoblastoma/pathology , Tumor Cells, Cultured
19.
FASEB J ; 15(2): 303-5, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11156944

ABSTRACT

Ectodomain shedding of cell surface membrane-anchoring proteins is an important process in a wide variety of physiological events(1, 2). Tumor necrosis factor alpha (TNF-alpha) converting enzyme (TACE) is the first discovered mammalian sheddase responsible for cleavage of several important surface proteins, including TNF-alpha, TNF p75 receptor, L-selectin, and transforming growth factor-a. Phorbol myristate acetate (PMA) has long been known as a potent agent to enhance ectodomain shedding. However, it is not fully understood how PMA activates TACE and induces ectodomain shedding. Here, we demonstrate that PMA induces both reactive oxygen species (ROS) generation and TNF p75 receptor shedding in Mono Mac 6 cells, a human monocytic cell line, and l-selectin shedding in Jurkat T-cells. ROS scavengers significantly attenuated PMA-induced TNF p75 receptor shedding. Exogenous H2O2 mimicked PMA-induced enhancement of ectodomain shedding, and H2O2-induced shedding was blocked by TAPI, a TACE inhibitor. Furthermore, both PMA and H2O2 failed to cause ectodomain shedding in a cell line that lacks TACE activity. By use of an in vitro TACE cleavage assay, H2O2 activated TACE that had been rendered inactive by the addition of the TACE inhibitory pro-domain sequence. We presume that the mechanism of TACE activation by H2O2 is due to an oxidative attack of the pro-domain thiol group and disruption of its inhibitory coordination with the Zn++ in the catalytic domain of TACE. These results demonstrate that ROS production is involved in PMA-induced ectodomain shedding and implicate a role for ROS in other shedding processes.


Subject(s)
Antigens, CD/physiology , Metalloendopeptidases/metabolism , Monocytes/physiology , Reactive Oxygen Species , Receptors, Tumor Necrosis Factor/physiology , Tetradecanoylphorbol Acetate/pharmacology , ADAM Proteins , ADAM17 Protein , Acetylcysteine/pharmacology , Antigens, CD/drug effects , Antioxidants/pharmacology , Cell Line , Cycloheximide/pharmacology , Dipeptides/pharmacology , Enzyme Activation , Humans , Hydrogen Peroxide/pharmacology , Hydroxamic Acids/pharmacology , Jurkat Cells , Models, Biological , Monocytes/drug effects , Protease Inhibitors/pharmacology , Receptors, Tumor Necrosis Factor/drug effects , Receptors, Tumor Necrosis Factor, Type II , Superoxide Dismutase/pharmacology , Tumor Necrosis Factor-alpha/physiology
20.
Ann Thorac Surg ; 70(2): 407-11, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10969653

ABSTRACT

BACKGROUND: Malignant mesothelioma is an uncommon but lethal cancer of increasing incidence, particularly among patients with a history of exposure to asbestos. Although numerous treatments have been employed, including chemotherapy, radiation therapy, surgical resection, and combinations of the above, no satisfactory treatment yet exists, and affected patients will die of this disease, usually within 12 months. Gene-based therapies constitute a new approach that offers hope of improved control of these tumors while being associated with less morbidity than conventional chemotherapeutic or surgical regimens. We demonstrated that PA1-STK cells home in vivo to mesothelioma deposits, a phenomenon that is required for optimal exertion of this therapeutic concept. METHODS: Gene-modified ovarian cancer cells expressing the thymidine-kinase gene (PA1-STK) were radiolabeled with 99Tc and infused into the pleural space of 4 patients with malignant pleural mesothelioma, then scanned to determine distribution of the cells. RESULTS: PA1-STK cells recognized and adhered preferentially to mesothelioma lining the chest wall. CONCLUSIONS: Cell-based "suicide gene" therapy utilizing the "bystander effect" with the gene-modified ovarian cancer cell line PA1-STK is feasible in human pleural mesothelioma. We have shown that this trafficking and homing of the therapeutic cells to the intrapleural tumor sites, a requirement for success with this novel therapeutic concept, is also valid in humans.


Subject(s)
Genetic Therapy , Mesothelioma/therapy , Pleural Neoplasms/therapy , Simplexvirus/genetics , Thymidine Kinase/genetics , Female , Humans , Mesothelioma/diagnostic imaging , Mesothelioma/pathology , Ovarian Neoplasms/genetics , Pleural Neoplasms/diagnostic imaging , Pleural Neoplasms/pathology , Radiopharmaceuticals , Technetium Compounds , Tomography, Emission-Computed, Single-Photon , Transduction, Genetic , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...